WO2012176792A1 - 炎症性疾患、アレルギー性疾患および自己免疫疾患用途のための医薬組成物 - Google Patents
炎症性疾患、アレルギー性疾患および自己免疫疾患用途のための医薬組成物 Download PDFInfo
- Publication number
- WO2012176792A1 WO2012176792A1 PCT/JP2012/065706 JP2012065706W WO2012176792A1 WO 2012176792 A1 WO2012176792 A1 WO 2012176792A1 JP 2012065706 W JP2012065706 W JP 2012065706W WO 2012176792 A1 WO2012176792 A1 WO 2012176792A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical composition
- composition according
- group
- alkyl
- fatty acid
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 43
- 208000023275 Autoimmune disease Diseases 0.000 title claims abstract description 16
- 208000026935 allergic disease Diseases 0.000 title claims abstract description 16
- 208000027866 inflammatory disease Diseases 0.000 title claims abstract description 13
- 239000000194 fatty acid Substances 0.000 claims abstract description 41
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 39
- 229930195729 fatty acid Natural products 0.000 claims abstract description 39
- 150000004665 fatty acids Chemical class 0.000 claims abstract description 39
- 238000000034 method Methods 0.000 claims abstract description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 45
- -1 3,3-ethylenedioxydecyl Chemical group 0.000 claims description 40
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 34
- 201000004624 Dermatitis Diseases 0.000 claims description 25
- 125000003545 alkoxy group Chemical group 0.000 claims description 22
- 125000000623 heterocyclic group Chemical group 0.000 claims description 22
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 20
- 229910052799 carbon Inorganic materials 0.000 claims description 20
- 125000004432 carbon atom Chemical group C* 0.000 claims description 20
- 125000003118 aryl group Chemical group 0.000 claims description 19
- 201000004384 Alopecia Diseases 0.000 claims description 18
- 229910052736 halogen Inorganic materials 0.000 claims description 18
- 150000002367 halogens Chemical class 0.000 claims description 18
- 229920006395 saturated elastomer Polymers 0.000 claims description 18
- 125000004043 oxo group Chemical group O=* 0.000 claims description 16
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 15
- 239000001257 hydrogen Substances 0.000 claims description 15
- 229910052739 hydrogen Inorganic materials 0.000 claims description 15
- 125000004423 acyloxy group Chemical group 0.000 claims description 14
- 125000002947 alkylene group Chemical group 0.000 claims description 14
- 231100000360 alopecia Toxicity 0.000 claims description 14
- 229910052760 oxygen Inorganic materials 0.000 claims description 13
- 239000001301 oxygen Substances 0.000 claims description 13
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 claims description 11
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 10
- 125000004104 aryloxy group Chemical group 0.000 claims description 10
- 201000008937 atopic dermatitis Diseases 0.000 claims description 10
- KPSZWAJWFMFMFF-UHFFFAOYSA-N hept-5-enoic acid Chemical compound CC=CCCCC(O)=O KPSZWAJWFMFMFF-UHFFFAOYSA-N 0.000 claims description 10
- 230000001506 immunosuppresive effect Effects 0.000 claims description 10
- 229910052757 nitrogen Inorganic materials 0.000 claims description 10
- 206010062016 Immunosuppression Diseases 0.000 claims description 9
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 9
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 9
- 229910052717 sulfur Inorganic materials 0.000 claims description 9
- 239000011593 sulfur Substances 0.000 claims description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 7
- 150000002431 hydrogen Chemical class 0.000 claims description 7
- 150000001721 carbon Chemical group 0.000 claims description 6
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims description 5
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 3
- 125000001931 aliphatic group Chemical group 0.000 claims description 2
- 230000036039 immunity Effects 0.000 abstract description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 45
- 239000000203 mixture Substances 0.000 description 32
- 150000001875 compounds Chemical class 0.000 description 29
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 24
- 239000000243 solution Substances 0.000 description 24
- 229940126062 Compound A Drugs 0.000 description 21
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 21
- 210000001744 T-lymphocyte Anatomy 0.000 description 19
- 230000006698 induction Effects 0.000 description 19
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 17
- 230000003779 hair growth Effects 0.000 description 17
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 16
- 230000002829 reductive effect Effects 0.000 description 16
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 208000024891 symptom Diseases 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 210000003719 b-lymphocyte Anatomy 0.000 description 12
- 229940053200 antiepileptics fatty acid derivative Drugs 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 150000003839 salts Chemical class 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 8
- 230000006399 behavior Effects 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000012044 organic layer Substances 0.000 description 8
- 125000001424 substituent group Chemical group 0.000 description 8
- 239000000427 antigen Substances 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 7
- 235000019341 magnesium sulphate Nutrition 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- HJRJRUMKQCMYDL-UHFFFAOYSA-N 1-chloro-2,4,6-trinitrobenzene Chemical compound [O-][N+](=O)C1=CC([N+]([O-])=O)=C(Cl)C([N+]([O-])=O)=C1 HJRJRUMKQCMYDL-UHFFFAOYSA-N 0.000 description 6
- 208000032843 Hemorrhage Diseases 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 6
- 239000000654 additive Substances 0.000 description 6
- 150000005215 alkyl ethers Chemical class 0.000 description 6
- 208000034158 bleeding Diseases 0.000 description 6
- 230000000740 bleeding effect Effects 0.000 description 6
- 230000007547 defect Effects 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 150000002430 hydrocarbons Chemical group 0.000 description 6
- 239000002674 ointment Substances 0.000 description 6
- 238000010898 silica gel chromatography Methods 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 229960001967 tacrolimus Drugs 0.000 description 6
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 230000010261 cell growth Effects 0.000 description 5
- 229940125773 compound 10 Drugs 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 4
- PHEDXBVPIONUQT-UHFFFAOYSA-N Cocarcinogen A1 Natural products CCCCCCCCCCCCCC(=O)OC1C(C)C2(O)C3C=C(C)C(=O)C3(O)CC(CO)=CC2C2C1(OC(C)=O)C2(C)C PHEDXBVPIONUQT-UHFFFAOYSA-N 0.000 description 4
- 108010057466 NF-kappa B Proteins 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 125000005907 alkyl ester group Chemical group 0.000 description 4
- 108010005774 beta-Galactosidase Proteins 0.000 description 4
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 208000024963 hair loss Diseases 0.000 description 4
- 125000005843 halogen group Chemical group 0.000 description 4
- 125000005842 heteroatom Chemical group 0.000 description 4
- 239000003701 inert diluent Substances 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 4
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 4
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- WGJJROVFWIXTPA-OALUTQOASA-N prostanoic acid Chemical compound CCCCCCCC[C@H]1CCC[C@@H]1CCCCCCC(O)=O WGJJROVFWIXTPA-OALUTQOASA-N 0.000 description 4
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- 229940104230 thymidine Drugs 0.000 description 4
- 210000001541 thymus gland Anatomy 0.000 description 4
- 206010003645 Atopy Diseases 0.000 description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 3
- 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 102100035194 Placenta growth factor Human genes 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000005299 abrasion Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 150000002170 ethers Chemical class 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 239000011737 fluorine Substances 0.000 description 3
- 230000003676 hair loss Effects 0.000 description 3
- 229960003444 immunosuppressant agent Drugs 0.000 description 3
- 239000003018 immunosuppressive agent Substances 0.000 description 3
- 101150066555 lacZ gene Proteins 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229960005205 prednisolone Drugs 0.000 description 3
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 150000003180 prostaglandins Chemical class 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 2
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 2
- SZNYYWIUQFZLLT-UHFFFAOYSA-N 2-methyl-1-(2-methylpropoxy)propane Chemical compound CC(C)COCC(C)C SZNYYWIUQFZLLT-UHFFFAOYSA-N 0.000 description 2
- MLOSJPZSZWUDSK-UHFFFAOYSA-N 4-carboxybutyl(triphenyl)phosphanium;bromide Chemical compound [Br-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(CCCCC(=O)O)C1=CC=CC=C1 MLOSJPZSZWUDSK-UHFFFAOYSA-N 0.000 description 2
- HIYAVKIYRIFSCZ-CYEMHPAKSA-N 5-(methylamino)-2-[[(2S,3R,5R,6S,8R,9R)-3,5,9-trimethyl-2-[(2S)-1-oxo-1-(1H-pyrrol-2-yl)propan-2-yl]-1,7-dioxaspiro[5.5]undecan-8-yl]methyl]-1,3-benzoxazole-4-carboxylic acid Chemical compound O=C([C@@H](C)[C@H]1O[C@@]2([C@@H](C[C@H]1C)C)O[C@@H]([C@@H](CC2)C)CC=1OC2=CC=C(C(=C2N=1)C(O)=O)NC)C1=CC=CN1 HIYAVKIYRIFSCZ-CYEMHPAKSA-N 0.000 description 2
- 101000605172 Aspergillus niger (strain CBS 513.88 / FGSC A1513) Probable endopolygalacturonase E Proteins 0.000 description 2
- 101000605171 Aspergillus niger Endopolygalacturonase E Proteins 0.000 description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
- 101000941281 Bos taurus Gastric triacylglycerol lipase Proteins 0.000 description 2
- 108010062580 Concanavalin A Proteins 0.000 description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- 108010036949 Cyclosporine Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 230000004568 DNA-binding Effects 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 102000003945 NF-kappa B Human genes 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 102000005936 beta-Galactosidase Human genes 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000003710 calcium ionophore Substances 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 229960001265 ciclosporin Drugs 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 229940125797 compound 12 Drugs 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 150000002169 ethanolamines Chemical class 0.000 description 2
- CJAONIOAQZUHPN-KKLWWLSJSA-N ethyl 12-[[2-[(2r,3r)-3-[2-[(12-ethoxy-12-oxododecyl)-methylamino]-2-oxoethoxy]butan-2-yl]oxyacetyl]-methylamino]dodecanoate Chemical compound CCOC(=O)CCCCCCCCCCCN(C)C(=O)CO[C@H](C)[C@@H](C)OCC(=O)N(C)CCCCCCCCCCCC(=O)OCC CJAONIOAQZUHPN-KKLWWLSJSA-N 0.000 description 2
- 125000004494 ethyl ester group Chemical group 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 230000005713 exacerbation Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000008105 immune reaction Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- FMKOJHQHASLBPH-UHFFFAOYSA-N isopropyl iodide Chemical compound CC(C)I FMKOJHQHASLBPH-UHFFFAOYSA-N 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- LJCNRYVRMXRIQR-OLXYHTOASA-L potassium sodium L-tartrate Chemical compound [Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O LJCNRYVRMXRIQR-OLXYHTOASA-L 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 229930195734 saturated hydrocarbon Natural products 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 235000011006 sodium potassium tartrate Nutrition 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 239000006190 sub-lingual tablet Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 125000003107 substituted aryl group Chemical group 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 230000037426 transcriptional repression Effects 0.000 description 2
- PYOKUURKVVELLB-UHFFFAOYSA-N trimethyl orthoformate Chemical compound COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 1
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
- PNKZBZPLRKCVLI-UHFFFAOYSA-N (2-methylpropan-2-yl)oxybenzene Chemical compound CC(C)(C)OC1=CC=CC=C1 PNKZBZPLRKCVLI-UHFFFAOYSA-N 0.000 description 1
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 1
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 1
- HXKKHQJGJAFBHI-UHFFFAOYSA-N 1-aminopropan-2-ol Chemical class CC(O)CN HXKKHQJGJAFBHI-UHFFFAOYSA-N 0.000 description 1
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
- POEDHWVTLBLWDA-UHFFFAOYSA-N 1-butylindole-2,3-dione Chemical compound C1=CC=C2N(CCCC)C(=O)C(=O)C2=C1 POEDHWVTLBLWDA-UHFFFAOYSA-N 0.000 description 1
- CMCBDXRRFKYBDG-UHFFFAOYSA-N 1-dodecoxydodecane Chemical compound CCCCCCCCCCCCOCCCCCCCCCCCC CMCBDXRRFKYBDG-UHFFFAOYSA-N 0.000 description 1
- ZXHQLEQLZPJIFG-UHFFFAOYSA-N 1-ethoxyhexane Chemical compound CCCCCCOCC ZXHQLEQLZPJIFG-UHFFFAOYSA-N 0.000 description 1
- FDCJDKXCCYFOCV-UHFFFAOYSA-N 1-hexadecoxyhexadecane Chemical compound CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC FDCJDKXCCYFOCV-UHFFFAOYSA-N 0.000 description 1
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 description 1
- UXPPDBVMSPAPCL-UHFFFAOYSA-N 1-prop-1-ynoxyprop-1-yne Chemical compound CC#COC#CC UXPPDBVMSPAPCL-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- PRHCBRXAHBBRKA-UHFFFAOYSA-N 2-(2-hydroxypropan-2-yloxy)propan-2-ol Chemical compound CC(C)(O)OC(C)(C)O PRHCBRXAHBBRKA-UHFFFAOYSA-N 0.000 description 1
- PLNNBRYFKARCEV-UHFFFAOYSA-N 2-[(2-hydroxyphenyl)methoxymethyl]phenol Chemical compound OC1=CC=CC=C1COCC1=CC=CC=C1O PLNNBRYFKARCEV-UHFFFAOYSA-N 0.000 description 1
- 125000000143 2-carboxyethyl group Chemical group [H]OC(=O)C([H])([H])C([H])([H])* 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- ATVJXMYDOSMEPO-UHFFFAOYSA-N 3-prop-2-enoxyprop-1-ene Chemical compound C=CCOCC=C ATVJXMYDOSMEPO-UHFFFAOYSA-N 0.000 description 1
- XHWSCQCJAPLELI-UHFFFAOYSA-N 4-(3,4-dimethoxyphenoxy)-1,2-dimethoxybenzene Chemical compound C1=C(OC)C(OC)=CC=C1OC1=CC=C(OC)C(OC)=C1 XHWSCQCJAPLELI-UHFFFAOYSA-N 0.000 description 1
- JLLYLQLDYORLBB-UHFFFAOYSA-N 5-bromo-n-methylthiophene-2-sulfonamide Chemical compound CNS(=O)(=O)C1=CC=C(Br)S1 JLLYLQLDYORLBB-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical class NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- RRSNDVCODIMOFX-MPKOGUQCSA-N Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O Chemical compound Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O RRSNDVCODIMOFX-MPKOGUQCSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 206010016946 Food allergy Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 102100031132 Glucose-6-phosphate isomerase Human genes 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 101150020741 Hpgds gene Proteins 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical group CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 description 1
- 102000005714 Keratin-2 Human genes 0.000 description 1
- 108010070520 Keratin-2 Proteins 0.000 description 1
- 102000005373 Keratin-3 Human genes 0.000 description 1
- 108010070918 Keratin-3 Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 108010018525 NFATC Transcription Factors Proteins 0.000 description 1
- 102000002673 NFATC Transcription Factors Human genes 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 206010030043 Ocular hypertension Diseases 0.000 description 1
- 101150080623 PGB gene Proteins 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010034277 Pemphigoid Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 101710191567 Probable endopolygalacturonase C Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 108010092262 T-Cell Antigen Receptors Proteins 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- QYKIQEUNHZKYBP-UHFFFAOYSA-N Vinyl ether Chemical compound C=COC=C QYKIQEUNHZKYBP-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- QUXMPZUVBXHUII-UHFFFAOYSA-N [1,1-bis(hydroxymethylamino)ethylamino]methanol Chemical class OCNC(C)(NCO)NCO QUXMPZUVBXHUII-UHFFFAOYSA-N 0.000 description 1
- PVQATPQSBYNMGE-UHFFFAOYSA-N [benzhydryloxy(phenyl)methyl]benzene Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)OC(C=1C=CC=CC=1)C1=CC=CC=C1 PVQATPQSBYNMGE-UHFFFAOYSA-N 0.000 description 1
- XXFXTBNFFMQVKJ-UHFFFAOYSA-N [diphenyl(trityloxy)methyl]benzene Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)OC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 XXFXTBNFFMQVKJ-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 150000003931 anilides Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 150000001483 arginine derivatives Chemical class 0.000 description 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 150000003939 benzylamines Chemical class 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical class CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 150000003946 cyclohexylamines Chemical class 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- AQEFLFZSWDEAIP-UHFFFAOYSA-N di-tert-butyl ether Chemical compound CC(C)(C)OC(C)(C)C AQEFLFZSWDEAIP-UHFFFAOYSA-N 0.000 description 1
- MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical compound C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical class OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- UZBQIPPOMKBLAS-UHFFFAOYSA-N diethylazanide Chemical compound CC[N-]CC UZBQIPPOMKBLAS-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 150000004656 dimethylamines Chemical class 0.000 description 1
- QKIUAMUSENSFQQ-UHFFFAOYSA-N dimethylazanide Chemical compound C[N-]C QKIUAMUSENSFQQ-UHFFFAOYSA-N 0.000 description 1
- POLCUAVZOMRGSN-UHFFFAOYSA-N dipropyl ether Chemical compound CCCOCCC POLCUAVZOMRGSN-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 239000008393 encapsulating agent Substances 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- ZCRZCMUDOWDGOB-UHFFFAOYSA-N ethanesulfonimidic acid Chemical compound CCS(N)(=O)=O ZCRZCMUDOWDGOB-UHFFFAOYSA-N 0.000 description 1
- LZTCEQQSARXBHE-UHFFFAOYSA-N ethoxycyclopropane Chemical compound CCOC1CC1 LZTCEQQSARXBHE-UHFFFAOYSA-N 0.000 description 1
- CQYBANOHCYKAEE-UHFFFAOYSA-N ethynoxyethyne Chemical compound C#COC#C CQYBANOHCYKAEE-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000003838 furazanyl group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000003752 improving hair Effects 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000006749 inflammatory damage Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000003519 mature b lymphocyte Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- JABGXPCRNXUENL-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1N=CNC2=NC=N[C]12 JABGXPCRNXUENL-UHFFFAOYSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 1
- NSPJNIDYTSSIIY-UHFFFAOYSA-N methoxy(methoxymethoxy)methane Chemical compound COCOCOC NSPJNIDYTSSIIY-UHFFFAOYSA-N 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 150000003956 methylamines Chemical class 0.000 description 1
- MGJXBDMLVWIYOQ-UHFFFAOYSA-N methylazanide Chemical compound [NH-]C MGJXBDMLVWIYOQ-UHFFFAOYSA-N 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- 229960000951 mycophenolic acid Drugs 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 125000004817 pentamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 229940048092 prednisolone 1 mg Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000003822 preparative gas chromatography Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 210000001948 pro-b lymphocyte Anatomy 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical class CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 230000001823 pruritic effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N purine-6-thione Natural products S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 238000006798 ring closing metathesis reaction Methods 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 150000005621 tetraalkylammonium salts Chemical class 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229920001567 vinyl ester resin Polymers 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 125000005023 xylyl group Chemical group 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
- C07D317/20—Free hydroxyl or mercaptan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
- A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
- C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
Definitions
- the present invention relates to a method and a pharmaceutical composition for immunosuppression with a fatty acid derivative having a specific structure.
- the invention further relates to methods and pharmaceutical compositions for the treatment of inflammatory, allergic and autoimmune diseases.
- Adaptive immune system cells are a specific type of white blood cell, called lymphocytes. Lymphocytes are roughly divided into B cells and T cells, both of which are derived from hematopoietic stem cells in the bone marrow, but B cells mature independently of the thymus, and T cells differentiate and mature in the thymus. Both recognize specific antigen targets, B cells are involved in the humoral immune response, and T cells are involved in the cellular immune response. B cells are differentiated into pre-B cells and mature B cells by stimulation of cytokines such as interleukins, and are activated by antigen stimulation, and finally become plasma cells capable of producing antibodies. .
- the T cells migrate to the thymus, and further undergo differentiation to become mature T cells.
- activated T cells are activated by antigen stimulation to become activated T cells having proliferation ability or cytotoxicity. Therefore, immunity can be suppressed by suppressing the proliferation of activated B cells and / or T cells.
- Inflammation is the first response the immune system makes to an infection or injury. Transient inflammation is effective in protecting against infection, etc., whereas uncontrolled inflammation damages tissues and is a potential factor in many diseases. Inflammation is usually caused by antigen binding to the T cell antigen receptor.
- Immune responses to foreign antigens such as bacteria and viruses protect and eliminate infection.
- abnormal immune responses that are not controlled cause allergic and autoimmune diseases.
- An allergic disease is a disease in which an immune reaction occurs excessively with respect to an antigen from the outside, and is characterized by activation of T cells and excessive production of IgE by B cells.
- an autoimmune disease is a disease in which an immune reaction occurs against an antigen derived from the self, and autoantibodies cause various disorders, characterized by activation of T cells and B cells and excessive production of inflammatory cytokines. is there.
- Allergic diseases and autoimmune diseases are closely related because they are caused by inflammation, and many allergic diseases, autoimmune diseases and diseases regarded as inflammatory diseases overlap.
- Fatty acid derivatives are a group of organic carboxylic acids that are contained in human or other mammalian tissues or organs and exhibit a wide range of physiological activities. Some naturally occurring fatty acid derivatives generally have a prostanoic acid skeleton as shown in formula (A).
- Natural PGs are classified into PGAs, PGBs, PGCs, PGDs, PGEs, PGFs, PGGs, PGHs, PGIs and PGJs according to the structural characteristics of the five-membered ring part, and the carbon chain part The following three types are classified according to the number and position of unsaturation. (Subscript 1). . . 13,14-unsaturated-15-OH (Subscript 2). . . 5,6- and 13,14-diunsaturated-15-OH (Subscript 3). . . 5,6-, 13,14- and 17,18-triunsaturated-15-OH
- PGFs are classified into ⁇ (hydroxyl group is alpha configuration) and ⁇ (hydroxyl group is beta configuration) according to the arrangement of the 9th and 11th hydroxyl groups.
- Patent Document 4 discloses that fatty acid derivatives having two heteroatoms in the 15th carbon are useful for promoting hair growth. Yes.
- An object of the present invention is to provide a method and a pharmaceutical composition for immunosuppression, and a method and a pharmaceutical composition for treating inflammatory diseases, allergic diseases and autoimmune diseases.
- the present inventor can suppress immunity by suppressing the proliferation of B cells and / or T cells in which fatty acid derivatives having a specific structure are activated, thereby having a specific structure.
- fatty acid derivatives are useful in the treatment of inflammatory diseases, allergic diseases and autoimmune diseases.
- a pharmaceutical composition for immunosuppression comprising a fatty acid derivative represented by the following general formula (I) as an active ingredient.
- L, M and N are hydrogen, hydroxy, halogen, lower alkyl, hydroxy (lower) alkyl, lower alkanoyloxy or oxo; wherein at least one of L and M is a group other than hydrogen;
- the member ring may have at least one double bond;
- A represents —CH 3, —CH 2 OH, —COCH 2 OH, —COOH or a functional derivative thereof;
- Z 1 and Z 2 are oxygen, nitrogen or sulfur;
- R 2
- Fatty acid derivative is isopropyl (Z) -7-[(1R, 2R, 3R, 5S) -2- (3,3-ethylenedioxydecyl) -3,5-dihydroxycyclopentyl] hept-5-enoate
- the pharmaceutical composition according to any one of (1) to (8) which is for treating an inflammatory disease.
- (11) The pharmaceutical composition according to (10), for treating alopecia associated with skin inflammation.
- (12) The pharmaceutical composition according to any one of (1) to (8), which is for treating allergic diseases.
- a method for immunosuppression in a mammalian subject comprising administering an effective amount of the fatty acid derivative represented by the general formula (I) described in (1) to a subject in need thereof.
- the above formula (A) has a basic skeleton of C-20, but the number of carbons is not limited by this in the present invention. That is, the numbers of carbons constituting the basic skeleton are 1 for carboxylic acid, 2 to 7 in order toward the 5-membered ring, carbon on the ⁇ chain, 8 to 12 for 5-membered carbon, and 13 to 20 for carbon. Is attached to the ⁇ chain, but when the carbon number decreases on the ⁇ chain, the number is deleted sequentially from the 2nd position, and when it increases on the ⁇ chain, it replaces the carboxyl group (1st position) at the 2nd position. It is named as having a substituent.
- PGD, PGE, and PGF refer to fatty acid derivatives having a hydroxyl group at the 9-position and / or the 11-position, but in the present invention, those having other groups instead of the 9-position and / or the 11-position hydroxyl group may also be used. Include. When naming these compounds, they are named in the form of 9-deoxy-9-substituted or 11-deoxy-11-substituted. In addition, when it has hydrogen instead of a hydroxyl group, it is simply called a 9 or 11-deoxy compound.
- the fatty acid derivative is named based on the prostanoic acid skeleton.
- the abbreviation “PG” is used for the sake of simplicity.
- the PG compound in which the ⁇ -chain skeleton carbon number is extended by two that is, the fatty acid derivative having the ⁇ -chain skeleton carbon number of 9, is a 2-decarboxy-2- (2-carboxyethyl) -PG compound. May be named.
- a fatty acid derivative having a skeleton carbon number of ⁇ chain of 11 may be named as 2-decarboxy-2- (4-carboxybutyl) -PG compound.
- a fatty acid derivative in which the number of skeletal carbon atoms of the ⁇ chain is extended by 2 that is, a fatty acid derivative having a skeletal carbon number of 10 in the ⁇ chain may be named 20-ethyl-PG compound. The naming can be performed based on the IUPAC nomenclature.
- the fatty acid derivative used in the present invention may include a substitution product or derivative of any fatty acid derivative.
- a fatty acid derivative having a double bond at the 13-14 position and a hydroxyl group at the 15 position a fatty acid derivative having another double bond at the 5-6 position, and a double bond at the 17-18 position.
- Examples of analogs containing a substituent or derivative include compounds in which the terminal carboxyl group of the ⁇ chain of the above compound is esterified or amidated, physiologically acceptable salts, carbon numbers of the ⁇ chain or ⁇ chain.
- the fatty acid derivatives used in the present invention are those represented by the following formula (I): Wherein L, M and N are hydrogen, hydroxy, halogen, lower alkyl, hydroxy (lower) alkyl, lower alkanoyloxy or oxo; wherein at least one of L and M is a group other than hydrogen;
- the member ring may have at least one double bond;
- A represents —CH 3, —CH 2 OH, —COCH 2 OH, —COOH or a functional derivative thereof;
- Z 1 and Z 2 are oxygen, nitrogen or sulfur;
- R 2 and R 3 are lower alkyl and may
- At least one carbon atom may be optionally substituted by oxygen, nitrogen or sulfur;
- R 4 is a single bond or lower alkylene; and
- R 5 is lower alkyl, lower alkoxy, lower alkanoyloxy, cyclo (lower) alkyl, cyclo (lower) alkyloxy, aryl, aryloxy, heterocyclic or heterocyclic oxy group].
- the term “unsaturated” in the definition of R 1 and Ra isolates one or more double and / or triple bonds as a bond between the main chain and / or side chain carbon atoms. , Means containing separately or sequentially. In accordance with normal nomenclature, unsaturated bonds between two consecutive positions are indicated by displaying the lower position number, and unsaturated bonds between two non-consecutive positions are indicated by displaying both position numbers.
- low to intermediate aliphatic hydrocarbon means a hydrocarbon group having a straight or branched chain having 1 to 14 carbon atoms (wherein the side chain is preferably one having 1 to 3 carbon atoms). Preferably, it is a hydrocarbon group having 1 to 10 carbon atoms, particularly 1 to 8 carbon atoms.
- halogen atom includes fluorine, chlorine, bromine and iodine.
- lower includes a group having 1 to 6 carbon atoms unless otherwise specified.
- lower alkyl means a straight or branched saturated hydrocarbon group having 1 to 6 carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl and hexyl. including.
- lower alkylene means a linear or branched divalent saturated hydrocarbon group having 1 to 6 carbon atoms, such as methylene, ethylene, propylene, isopropylene, butylene, isobutylene, t-butylene, Contains pentylene and hexylene.
- lower alkoxy means a lower alkyl-O— group wherein lower alkyl is as defined above.
- hydroxy (lower) alkyl means a lower alkyl as described above substituted with at least one hydroxy group, for example hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl and 1-methyl-1- Hydroxyethyl is mentioned.
- lower alkanoyloxy means a group represented by the formula RCO—O— (where RCO— is an acyl group formed by oxidation of a lower alkyl group as described above, for example, acetyl).
- cyclo (lower) alkyl means a cyclic group formed by ring closure of a lower alkyl group containing 3 or more carbon atoms, and includes, for example, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
- cyclo (lower) alkyloxy means a cyclo (lower) alkyl-O— group wherein cyclo (lower) alkyl is as defined above.
- aryl includes unsubstituted or substituted aromatic hydrocarbon ring groups (preferably monocyclic groups), for example phenyl, tolyl, xylyl.
- substituents include a halogen atom and halo (lower) alkyl (wherein the halogen atom and lower alkyl are as defined above).
- aryloxy means a group represented by the formula ArO— (wherein Ar is aryl as described above).
- heterocyclic group includes optionally substituted carbon atoms and 1 to 4 hetero atoms, preferably 1 to 3, selected from nitrogen, oxygen and sulfur atoms. 5 to 14 membered, preferably 5 to 10 membered, monocyclic to tricyclic, preferably monocyclic heterocyclic groups are included.
- Heterocyclic groups include furyl, thienyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, furazanyl, pyranyl, pyridyl, pyridazinyl, pyrimidyl, pyrazinyl 2-pyrrolinyl group, pyrrolidinyl group, 2-imidazolinyl group, imidazolidinyl group, 2-pyrazolinyl group, pyrazolidinyl group, piperidino group, piperazinyl group, morpholino group, indolyl group, benzothienyl group, quinolyl group, isoquinolyl group, purinyl group, Examples include quinazolinyl group, carbazolyl group, acridinyl group, phenanthridinyl group, benzimidazolyl group, benz
- heterocyclic oxy group means a group represented by the formula HcO— (where Hc is a heterocyclic group as described above).
- the term “functional derivative” of A includes salts (preferably pharmaceutically acceptable salts), ethers, esters and amides.
- Suitable "pharmaceutically acceptable salts” include conventional non-toxic salts, such as salts with inorganic bases, such as alkali metal salts (sodium salts, potassium salts, etc.), alkaline earth metal salts (calcium salts, Magnesium salts, etc.), ammonium salts; or salts with organic bases such as amine salts (eg methylamine salts, dimethylamine salts, cyclohexylamine salts, benzylamine salts, piperidine salts, ethylenediamine salts, ethanolamine salts, diethanolamine salts, Ethanolamine salt, tris (hydroxymethylamino) ethane salt, monomethyl-monoethanolamine salt, procaine salt, caffeine salt, etc.), basic amino acid salt (eg arginine salt, lysine salt, etc.), tetraalkylammonium salt, etc. It is done. These salts can be prepared, for example, from the corresponding acids and bases by conventional reactions
- ethers include alkyl ethers, for example, lower alkyl ethers such as methyl ether, ethyl ether, propyl ether, isopropyl ether, butyl ether, isobutyl ether, t-butyl ether, pentyl ether, 1-cyclopropyl ethyl ether; Intermediate or higher alkyl ethers such as ethylhexyl ether, lauryl ether, cetyl ether; unsaturated ethers such as oleyl ether and linolenyl ether; lower alkenyl ethers such as vinyl ether and allyl ether; lower alkynyl ethers such as ethynyl ether and propynyl ether; hydroxy Hydroxy (lower) alkyl ethers such as ethyl ether and hydroxyisopropyl ether; methoxymethyl ether, 1- Lower alkoxy (lower)
- Esters include methyl esters, ethyl esters, propyl esters, isopropyl esters, butyl esters, isobutyl esters, t-butyl esters, pentyl esters, 1-cyclopropylethyl esters and the like lower alkyl esters; vinyl esters, allyl esters and the like.
- the amide of A means a group represented by the formula —CONR′R ′′, wherein R ′ and R ′′ are hydrogen, lower alkyl, aryl, alkyl- or aryl-sulfonyl, lower alkenyl and lower alkynyl, respectively.
- R ′ and R ′′ are hydrogen, lower alkyl, aryl, alkyl- or aryl-sulfonyl, lower alkenyl and lower alkynyl, respectively.
- Examples thereof include lower alkylamides such as methylamide, ethylamide, dimethylamide, and diethylamide; arylamides such as anilide and toluidide; and alkyl- or aryl-sulfonylamides such as methylsulfonylamide, ethylsulfonylamide, and tolylsulfonylamide.
- L and M include hydrogen, hydroxy and oxo, particularly L is hydroxy and M is hydroxy.
- a preferred example of A is —COOH, a functional derivative thereof.
- B are —CH 2 —CH 2 —, —CH ⁇ CH— or —C ⁇ C—.
- a preferred example of Z 1 and Z 2 is both oxygen.
- R 2 and R 3 include those in which R 2 and R 3 are joined together to form lower alkylene, and more preferably those that form alkylene having 3 carbon atoms.
- X 1 and X 2 are hydrogen or halogen, more preferably, both are hydrogen or fluorine.
- Preferred R 1 is a hydrocarbon residue having 1 to 10 carbon atoms, particularly preferably 6 to 10 carbon atoms. At least one carbon atom in the aliphatic hydrocarbon may be substituted with oxygen, nitrogen or sulfur.
- R 1 examples include, for example: —CH 2 —CH 2 —CH 2 —CH 2 —CH 2 —CH 2 —CH 2 —, —CH 2 —CH ⁇ CH—CH 2 —CH 2 —CH 2 —, —CH 2 —CH 2 —CH 2 —CH ⁇ CH—, —CH 2 —C ⁇ C—CH 2 —CH 2 —CH 2 —, —CH 2 —CH 2 —CH 2 —CH 2 —O—CH 2 —, —CH 2 —CH ⁇ CH—CH 2 —O—CH 2 —, —CH 2 —C ⁇ C—CH 2 —O—CH 2 —, —CH 2 —CH 2 —CH 2 —CH 2 —CH 2 —CH 2 —CH 2 —, —CH 2 —CH ⁇ CH—CH 2 —CH 2 —CH 2 —CH 2 —, —CH 2 —CH ⁇ CH—CH 2 —CH 2 —CH 2 —CH 2
- Ra is a hydrocarbon having 1-10 carbon atoms, more preferably 1-8 carbon atoms. Ra may have 1 or 2 side chains having 1 carbon atom.
- the arrangement of the ring and ⁇ - and / or ⁇ -chain in the above formulas (I) and (II) may be the same as or different from the arrangement of natural PGs.
- the present invention also encompasses mixtures of compounds having a natural type configuration and compounds having a non-natural type configuration.
- isomers such as individual tautomers, mixtures or optical isomers, mixtures, racemates and other stereoisomers can be used for the same purpose.
- the fatty acid derivative of the present invention is useful as a pharmaceutical composition for immunosuppression, and further useful as a pharmaceutical composition for the treatment of inflammatory diseases, allergic diseases and autoimmune diseases.
- treatment and / or “improvement” referred to in the present invention includes all managements such as prevention, treatment, symptom reduction, symptom reduction, progression stoppage, etc. of the target disease.
- Inflammatory diseases to be treated in the present invention include arthritis such as rheumatoid arthritis, pneumonia, viral hepatitis, inflammation associated with infection, inflammatory bowel disease, nephritis such as glomerulonephritis, gastritis, vasculitis Dermatitis such as pancreatitis, peritonitis, bronchitis, myocarditis, encephalitis, psoriasis, contact dermatitis, and the like.
- treatment of inflammatory diseases includes treatment of symptoms associated with inflammatory diseases, such as treatment of alopecia associated with dermatitis (such as dwarf alopecia, seborrheic alopecia, scarring alopecia, etc.). Is included.
- allergic diseases to be treated in the present invention include allergic conjunctivitis, allergic rhinitis, bronchial asthma, atopic dermatitis, food allergy, hay fever and the like.
- treatment of allergic diseases includes treatment of symptoms associated with allergic diseases, such as treatment of alopecia associated with atopic dermatitis.
- autoimmune diseases to be treated in the present invention include systemic lupus erythematosus, Sjogren's syndrome, multiple sclerosis, rheumatoid arthritis, pemphigoid, scleroderma, and ulcerative colitis.
- the treatment of autoimmune diseases includes treatment of symptoms associated with autoimmune diseases.
- the concentration of the fatty acid derivative used in the present invention varies depending on the compound used, the type of subject, age, body weight, symptoms to be treated, desired therapeutic effect, administration volume, treatment period, etc., and an appropriate dose is appropriately selected. sell.
- the fatty acid derivative of the present invention is administered at a dose of about 0.001 ⁇ g / kg to about 500 mg / kg per day, preferably about 0.01 ⁇ g / kg to about 50 mg / kg per day, once to 4 times a day.
- sufficient effects can be obtained by local administration or continuous administration.
- the fatty acid derivative can be applied systemically or locally.
- the fatty acid derivative can be administered by topical administration, oral administration, intranasal administration, buccal administration, administration by inhalation.
- the fatty acid derivative is preferably formulated as a pharmaceutical composition suitable for administration by conventional methods.
- the composition is suitable for topical administration, oral administration, intranasal administration, buccal administration, administration by inhalation, intravenous injection (including infusion), subcutaneous injection or perfusion, as well as rectal administration, vaginal administration, It may be a topical drug, suppository or suppository suitable for transdermal administration.
- the pharmaceutical composition of the present invention may further contain a physiologically acceptable additive.
- additives include components used with the compounds of the invention, such as excipients, diluents, extenders, solvents, lubricants, adjuvants, binders, disintegrants, coating agents, encapsulating agents, ointment bases.
- These additives are well known to those skilled in the art, and may be selected from those described in general pharmaceutical literature.
- the amount of the fatty acid derivative defined above in the pharmaceutical composition of the present invention may vary depending on the formulation of the composition, and is generally 0.001 to 10.0 w / v%, more preferably 0.005 to 5. It may be 0 w / v%, most preferably 0.01 to 1.0 w / v%.
- solid compositions for oral administration include tablets, troches, sublingual tablets, capsules, pills, powders, granules and the like.
- a solid composition may be prepared by mixing one or more active ingredients with at least one inert diluent.
- the composition may further include additives other than inert diluents, such as lubricants, disintegrants and stabilizers.
- Tablets and pills may be coated with enteric or gastroenteric films as desired. They may be covered by two or more layers. They can be absorbed into sustained-release materials or microencapsulated.
- the present composition may be encapsulated using an easily decomposable substance such as gelatin. They may be further dissolved in a suitable solvent such as fatty acid or its mono-, di- or triglycerides to form soft capsules. If immediate effect is required, sublingual tablets may be used.
- liquid compositions for oral administration include emulsions, solutions, suspensions, syrups and elixirs. Such compositions may further comprise a conventional inert diluent such as purified water or ethyl alcohol.
- the composition may contain additives other than inert diluents, for example, adjuvants such as wetting agents and suspending agents, sweeteners, flavoring agents, fragrances and preservatives.
- the pharmaceutical composition of the present invention may be in the form of a spray composition containing one or more active ingredients, which can be prepared by known methods.
- intranasal formulations may be aqueous or oily solutions, suspensions or emulsions containing one or more active ingredients.
- the compositions of the invention may be in the form of a suspension, solution or emulsion that can be provided as an aerosol, or in the form of a powder suitable for inhalation of a dry powder.
- a composition for administration by inhalation may further comprise a conventional propellant.
- Examples of the injectable composition of the present invention for parenteral administration include sterilized aqueous or non-aqueous solutions, suspensions and emulsions.
- Diluents for aqueous solutions or suspensions can include, for example, distilled water for injection, physiological saline, Ringer's solution, and the like.
- Non-aqueous diluents for solutions and suspensions can include, for example, propylene glycol, polyethylene glycol, vegetable oils (such as olive oil), alcohols (such as ethanol), and polysorbates.
- the composition may further contain additives such as preservatives, wetting agents, emulsifying agents, and dispersing agents. They may be sterilized, for example, by filtration through a bacteria-retaining filter, by incorporating a sterilizing agent, or by gas or radioisotope irradiation sterilization.
- injectable compositions can be provided as sterile powder compositions which can be dissolved in a sterile solvent for injection prior to use.
- the external medicine of the present invention includes all external preparations used in the fields of dermatology and otolaryngology, and includes ointments, creams, lotions and sprays.
- suppositories or suppositories which can be prepared by mixing the active ingredient with commonly used bases such as cocoa butter that softens at body temperature, improving absorption Therefore, a nonionic surfactant having an appropriate softening temperature may be used.
- composition of the present invention may further contain other components as long as the object of the present invention is not impaired.
- Concomitant administration means administration of another drug before, at the same time (same formulation or a combination of different formulations) or after administration of the fatty acid derivative of the present invention.
- Other drugs that can be administered in combination include, for example, steroids such as cortisol, prednisolone, triamcinolone, dexamethasone, immunosuppressants such as cyclosporine, tacrolimus, cyclophosphamide, and non-steroidal drugs such as aspirin, indomethacin, dichlorfenac Examples include anti-inflammatory analgesics.
- the solution was adjusted to pH 5 by adding ice-cold 1N aqueous hydrochloric acid dropwise at 0 ° C. to the residue.
- the solution was extracted with ethyl acetate and the organic layer was washed with a saturated aqueous sodium chloride solution, dried over magnesium sulfate and evaporated under reduced pressure.
- Ether was added to the residue, stirred for 17 hours at room temperature, and filtered through celite. The filtrate was evaporated under reduced pressure to give crude compound 9 (carboxylic acid).
- Test Example 1 (immunosuppressive effect)
- B cell growth inhibition test B lymphocyte cells isolated from the spleen of Balb / c mice (body weight 17 ⁇ 1 g), 2 ⁇ 10 6 / mL, pH 7 containing any concentration of Compound A and 10 mg / mL lipopolysaccharide (LPS) .4 After culturing at 37 ° C. for 24 hours in AIM-V medium, 120 nM 3 H thymidine was added and further cultured for 16 hours. The cells were collected by filtration and the cell growth inhibitory action was evaluated by measuring the thymidine incorporation into the cells using a liquid scintillation counter, and the IC 50 was determined. The results are shown in Table 1 and FIG.
- T cell growth inhibition test T lymphocyte cells isolated from the thymus of Balb / c mice (body weight 17 ⁇ 1 g), 5 ⁇ 10 6 / mL, compound A and 3.3 mg / mL concanavalin A (Con A) at any concentration After culturing at 37 ° C. for 24 hours in the pH7.4 AIM-V medium containing the mixture, 120 nM 3 H thymidine was added, and further cultured for 16 hours. The cells were collected by filtration and the cell growth inhibitory action was evaluated by measuring the thymidine incorporation into the cells using a liquid scintillation counter, and the IC 50 was determined. The results are shown in Table 1 and FIG.
- NF-AT gene transcription repression test Human T lymphocyte Jurkat cells transformed with ⁇ -galactosidase gene (lacZ) having the DNA binding site of transcription factor NFAT-1 in the transcriptional regulatory region, 2.3 x 10 6 / mL, pH 7. 4. Incubate with 0.5 mM A23187 (Calcium ionophore) and 50 ng / mL PMA (Phorbol 12-myristate 13-acetate) together with any concentration of Compound A in RPMI-1640 medium at 37 ° C for 20 minutes. In addition, the cells were further cultured for 4 hours.
- lacZ ⁇ -galactosidase gene
- ⁇ -galactosidase activity was measured by conversion to the fluorescent dye from FDG (fluorochrome di-beta-D-galactopyranoside), fluorescence was measured using a Spectrofluor Plus plate reader, it was determined and IC 50 .
- FDG fluorochrome di-beta-D-galactopyranoside
- NF- ⁇ B gene transcription repression test Human T lymphocyte Jurkat cells transformed with ⁇ -galactosidase gene (lacZ), which has the DNA binding site of transcription factor NF- ⁇ B in the transcriptional regulatory region, 2.3 x 10 6 / mL, pH 7. 4. Incubate with 0.5 mM A23187 (Calcium ionophore) and 50 ng / mL PMA (Phorbol 12-myristate 13-acetate) together with any concentration of Compound A in RPMI-1640 medium at 37 ° C for 20 minutes. In addition, the cells were further cultured for 4 hours.
- lacZ ⁇ -galactosidase gene
- ⁇ -galactosidase activity was measured by conversion to the fluorescent dye from FDG (fluorochrome di-beta-D-galactopyranoside), fluorescence was measured using a Spectrofluor Plus plate reader, it was determined and IC 50 .
- FDG fluorochrome di-beta-D-galactopyranoside
- NF-kB a pleiotropic mediator of inducible and tissue specific gene control.
- Test example 2 (atopic dermatitis mouse model test) A mouse (NC / NgaTndCrlj, male) model of picryl chloride (PiCl) -induced atopic dermatitis was used to assess the effect on skin inflammation and the condition of hair in skin-inflamed skin.
- mice were sensitized by applying PiCl solution to the shaved abdomen and toes, and 5 days after sensitization, the shaved back and left and right ears (internal and external) The induction was repeated by applying a PiCl solution on both sides. Each group was administered once a day for 28 days from 18 days after PiCl sensitization. Compound A and tacrolimus ointment 0.1% were applied openly to a model animal on the back of the neck of about 3 cm ⁇ about 5 cm.
- the dermatitis score and the hair growth score were used for each evaluation. Each score was scored according to the following criteria for dermatitis and hair growth / hair growth on the first, eighth, fifteenth, twenty-second and twenty-nine days (the day after the last administration).
- Edema Qualitative observation of the edema of the auricle, the induction site 0: Asymptomatic: No thickness observed on left and right pinna 1: Mild: Slightly thick on either the left or right 2: Moderate: Clear thickness and tension in any pinna 3: Severe: Clear thickness, tension, and warp in any pinna, and firmness when touched with a finger (4) Scratch / tissue defect: Scratch and tissue defect symptoms at the induction site Observe 0: Asymptomatic: No state of scratch or tissue defect at the induction site 1: Mild: Locally observed at the induction site, non-continuous scratches, no tissue defects 2: Moderate: Scattered at the site of induction, or small continuous scratches, no tissue defects 3: Severe: Overall state at the induction site or widespread continuous scratches and tissue defects (5) Crust formation /
- ⁇ Hair growth and hair growth state The transdermal administration area (neck back: about 3 cm ⁇ about 5 cm) of each individual was used as the observation area.
- the compound A administration group tends to suppress the exacerbation of initial dermatitis with respect to the compound A base group. Moreover, it turns out that the exacerbation of the initial stage dermatitis is suppressed significantly in the combined use group of the compound A and tacrolimus ointment compared with the compound A base group.
- the fatty acid derivative of the present invention has the possibility of suppressing aggravation of dermatitis such as atopic property, and that an effect on atopic dermatitis can be expected by using an immunosuppressant in combination.
- the hair growth score decreased (hair loss progressed) as the dermatitis score increased (deterioration of dermatitis) and after the administration 15 days and 22 days and 29 days of administration.
- the hair growth score increased on the 22nd and 29th day of administration
- the hair growth score increased on the 29th day of administration (improved hair loss) compared to the 22nd day of administration. I understand that it is recognized. This effect is observed in a dose-dependent manner in the compound A administration group, and is also observed in the combination group with prednisolone and tacrolimus ointment.
- the fatty acid derivative of the present invention can suppress / improve the progression of hair loss associated with worsening skin inflammation, and can be used in combination with steroids and immunosuppressants. Especially for the alopecia associated with (atopic) dermatitis that requires treatment of dermatitis itself, the fatty acid derivative of the present invention can make it possible to suppress and improve hair loss even when skin inflammation worsens. I understand.
Abstract
Description
(下付1)...13,14-不飽和-15-OH
(下付2)...5,6-および13,14-ジ不飽和-15-OH
(下付3)...5,6-、13,14-および17,18-トリ不飽和-15-OH
(1)下記一般式(I)で表される脂肪酸誘導体を有効成分として含有する免疫抑制するための医薬組成物。
[式中、L、MおよびNは、水素、ヒドロキシ、ハロゲン、低級アルキル、ヒドロキシ(低級)アルキル、低級アルカノイルオキシまたはオキソ; ここで、LおよびMの少なくとも一方は水素以外の基であり、5員環は少なくとも1つの二重結合を有していてもよい;
Aは、-CH3、-CH2OH、-COCH2OH、-COOH またはそれらの官能性誘導体;
Bは、単結合、-CH2-CH2-、-CH=CH-、-C≡C-、-CH2-CH2-CH2-、-CH=CH-CH2-、-CH2-CH=CH-、-C≡C-CH2-または-CH2-C≡C-;
Z1およびZ2は、酸素、窒素または硫黄;
R2およびR3は低級アルキルであり、一緒につながって低級アルキレンを形成してもよい;
R1は、非置換またはハロゲン、アルキル、ヒドロキシ、オキソ、アリールまたは複素環基で置換された、飽和または不飽和の二価の低~中級脂肪族炭化水素であり、脂肪族炭化水素における少なくとも1つの炭素原子は酸素、窒素または硫黄で置換されていてもよい;および、
Raは、非置換またはハロゲン、オキソ、ヒドロキシ、低級アルキル、低級アルコキシ、低級アルカノイルオキシ、シクロ(低級)アルキル、シクロ(低級)アルキルオキシ、アリール、アリールオキシ、複素環基または複素環オキシ基で置換された飽和または不飽和の低~中級脂肪族炭化水素残基; 低級アルコキシ; 低級アルカノイルオキシ; シクロ(低級)アルキル; シクロ(低級)アルキルオキシ; アリール; アリールオキシ; 複素環基; 複素環オキシ基;]。
(2)LおよびMがヒドロキシである、(1)記載の医薬組成物。
(3)Aが-COOH またはその官能性誘導体である、(1)または(2)記載の医薬組成物。
(4)Bが-CH2-CH2-、-CH=CH-または-C≡C-である、(1)~(3)のいずれかに記載の医薬組成物。
(5)Z1およびZ2が酸素である、(1)~(4)のいずれかに記載の医薬組成物。
(6)R2およびR3が一緒につながって低級アルキレンを形成する、(1)~(5)のいずれかに記載の医薬組成物。
(7)低級アルキレンが炭素数3のアルキレンである、(6)記載の医薬組成物。
(8)脂肪酸誘導体がイソプロピル (Z)-7-[(1R,2R,3R,5S)-2-(3,3-エチレンジオキシデシル)-3,5-ジヒドロキシシクロペンチル]ヘプト-5-エノエートである、(1)~(7)のいずれかに記載の医薬組成物。
(9)炎症性疾患を処置するためのものである、(1)~(8)のいずれかに記載の医薬組成物。
(10)皮膚の炎症またはそれに伴う脱毛症を処置するためのものである、(9)記載の医薬組成物。
(11)皮膚の炎症に伴う脱毛症を処置するためのものである、(10)記載の医薬組成物。
(12)アレルギー性疾患を処置するためのものである、(1)~(8)のいずれかに記載の医薬組成物。
(13)アトピー性皮膚炎またはそれに伴う脱毛症を処置するためのものである、(12)記載の医薬組成物。
(14)アトピー性皮膚炎に伴う脱毛症を処置するためのものである、(13)記載の医薬組成物。
(15)自己免疫疾患を処置するためのものである、(1)~(8)のいずれかに記載の医薬組成物。
(16)有効量の(1)記載の一般式(I)で表される脂肪酸誘導体を必要とする対象に投与することを含む、哺乳類対象において免疫抑制する方法。
(17)哺乳類対象において免疫抑制するための、(1)記載の一般式(I)で表される脂肪酸誘導体の使用。
Aは、-CH3、-CH2OH、-COCH2OH、-COOH またはそれらの官能性誘導体;
Bは、単結合、-CH2-CH2-、-CH=CH-、-C≡C-、-CH2-CH2-CH2-、-CH=CH-CH2-、-CH2-CH=CH-、-C≡C-CH2-または-CH2-C≡C-;
Z1およびZ2は、酸素、窒素または硫黄;
R2およびR3は低級アルキルであり、一緒につながって低級アルキレンを形成してもよい;
R1は、非置換またはハロゲン、アルキル、ヒドロキシ、オキソ、アリールまたは複素環基で置換された、飽和または不飽和の二価の低~中級脂肪族炭化水素であり、脂肪族炭化水素における少なくとも1つの炭素原子は酸素、窒素または硫黄で置換されていてもよい;および、
Raは、非置換またはハロゲン、オキソ、ヒドロキシ、低級アルキル、低級アルコキシ、低級アルカノイルオキシ、シクロ(低級)アルキル、シクロ(低級)アルキルオキシ、アリール、アリールオキシ、複素環基または複素環オキシ基で置換された飽和または不飽和の低~中級脂肪族炭化水素残基; 低級アルコキシ; 低級アルカノイルオキシ; シクロ(低級)アルキル; シクロ(低級)アルキルオキシ; アリール; アリールオキシ; 複素環基; 複素環オキシ基]。
[式中、LおよびMは、水素、ヒドロキシ、ハロゲン、低級アルキル、ヒドロキシ(低級)アルキル、低級アルカノイルオキシまたはオキソ、ここで、LおよびMの少なくとも一方は水素以外の基であり、5員環は少なくとも1つの二重結合を有していてもよい;
Aは、-CH3、-CH2OH、-COCH2OH、-COOH またはそれらの官能性誘導体;
Bは、単結合、-CH2-CH2-、-CH=CH-、-C≡C-、-CH2-CH2-CH2-、-CH=CH-CH2-、-CH2-CH=CH-、-C≡C-CH2-または-CH2-C≡C-;
Z1およびZ2は、酸素、窒素または硫黄;
R2およびR3は低級アルキルであり、一緒につながって低級アルキレンを形成してもよい;
X1およびX2は、水素、低級アルキルまたはハロゲン;
R1は、非置換またはハロゲン、アルキル、ヒドロキシ、オキソ、アリールまたは複素環で置換された、二価の飽和または不飽和の低~中級の脂肪族炭化水素残基であり、脂肪族炭化水素における少なくとも1つの炭素原子は任意に酸素、窒素または硫黄によって置換されていてもよい;
R4は、単結合または低級アルキレン;そして、
R5は、低級アルキル、低級アルコキシ、低級アルカノイルオキシ、シクロ(低級)アルキル、シクロ(低級)アルキルオキシ、アリール、アリールオキシ、複素環または複素環オキシ基]。
-CH2-CH2-CH2-CH2-CH2-CH2-、
-CH2-CH=CH-CH2-CH2-CH2-、
-CH2-CH2-CH2-CH2-CH=CH-、
-CH2-C≡C-CH2-CH2-CH2-、
-CH2-CH2-CH2-CH2-O-CH2-、
-CH2-CH=CH-CH2-O-CH2-、
-CH2-C≡C-CH2-O-CH2-、
-CH2-CH2-CH2-CH2-CH2-CH2-CH2-、
-CH2-CH=CH-CH2-CH2-CH2-CH2-、
-CH2-CH2-CH2-CH2-CH2-CH=CH-、
-CH2-C≡C-CH2-CH2-CH2-CH2-、
-CH2-CH2-CH2-CH2-CH2-CH(CH3)-CH2-、
-CH2-CH2-CH2-CH2-CH(CH3)-CH2-、
-CH2-CH2-CH2-CH2-CH2-CH2-CH2-CH2-、
-CH2-CH=CH-CH2-CH2-CH2-CH2-CH2-、
-CH2-CH2-CH2-CH2-CH2-CH2-CH=CH-、
-CH2-C≡C-CH2-CH2-CH2-CH2-CH2-、および、
-CH2-CH2-CH2-CH2-CH2-CH2-CH(CH3)-CH2-。
イソプロピル (5Z)-7-[(1R,2R,3R,5S)-2-[2-(2-ヘプチル-1,3-ジオキサン-2-イル)エチル]-3,5-ジヒドロキシシクロペンチル]ヘプト-5-エノエート (5)
イソプロピル (5Z)-7-[(1R,2R,3R,5S)-3,5-ジヒドロキシ-2-{2-[2-(2-フェニルエチル)-1,3-ジオキソラン-2-イル]エチル}シクロペンンチル]ペプト-5-エノエート (12)
化合物 12を合成例 1と同様にして化合物 11から調製した。
I.B細胞増殖抑制試験
Balb/cマウス(体重17±1g)の脾臓から単離したBリンパ球細胞、2x106/mLを、任意の濃度の化合物A及び10mg/mLリポ多糖(LPS)を含むpH7.4 AIM-V培地中で37°C、24時間培養後、120nM3Hチミジンを加え、16時間さらに培養した。細胞をフィルター濾過で集め、液体シンチレーションカウンターを用いて、チミジンの細胞への取り込みを測定することで、細胞増殖抑制作用を評価し、IC50を求めた。結果を表1及び図1に示す。
Balb/cマウス(体重17±1g)の胸腺から単離したTリンパ球細胞、5x106/mLを、任意の濃度の化合物A及び3.3mg/mL コンカナバリンA(Con A)を含むpH7.4 AIM-V培地中で37°C、24時間培養後、120nM3Hチミジンを加え、16時間さらに培養した。細胞をフィルター濾過で集め、液体シンチレーションカウンターを用いて、チミジンの細胞への取り込みを測定することで、細胞増殖抑制作用を評価し、IC50を求めた。結果を表1及び図2に示す。
転写因子NFAT-1のDNA結合部位を転写制御領域に持つβ-ガラクトシダーゼ遺伝子(lacZ)で形質転換したヒトTリンパ球Jurkat細胞、2.3 x 106 /mLを、pH7.4、RPMI-1640培地中で、任意の濃度の化合物Aとともに、37°C、20分、培養後、0.5 mM A23187(Calcium ionophore)及び50 ng /mL PMA(Phorbol 12-myristate 13-acetate) を加え、4時間さらに培養した。βガラクトシダーゼ活性は、FDG(蛍光色素ジ-β-D-ガラクトピラノシド)からの蛍光色素への変換で測定し、蛍光発光は、SpectroFluor Plus plate reader を用いて測定し、IC50を求めた。結果を表1及び図3に示す。
転写因子NF-κBのDNA結合部位を転写制御領域に持つβ-ガラクトシダーゼ遺伝子(lacZ)で形質転換したヒトTリンパ球Jurkat細胞、2.3 x 106 /mLを、pH7.4、RPMI-1640培地中で、任意の濃度の化合物Aとともに、37°C、20分、培養後、0.5 mM A23187(Calcium ionophore)及び50 ng /mL PMA(Phorbol 12-myristate 13-acetate) を加え、4時間さらに培養した。βガラクトシダーゼ活性は、FDG(蛍光色素ジ-β-D-ガラクトピラノシド)からの蛍光色素への変換で測定し、蛍光発光は、SpectroFluor Plus plate reader を用いて測定し、IC50を求めた。結果を表1及び図4に示す。
-3,5-ジヒドロキシシクロペンチル]ヘプト-5-エノエート
文献
1)Dayton JS, Turka LA, Thompson CB and Mitchell BS (1992) Comparison of
the effects of myoribine with those of zothiaprine, 6 mercaptopurine and
mycophenolic acid on T-lymphocyte proliferation and purine ribonucleotide
metabolism. Mol Pharmacol. 1992;41:671-676.
2)Mishell BB, Shiigi SM and Eds (1980) Cell Proliferation in Selected Methods in Cellular Immunology, V, XXIX, W.H. Freeman Co., San Francisco, CA. pp153-160.
3)Emmel EA, Verweij CL, Durand DB, Higgins KM, Lacy E and Crabtree GR (1989) Cyclosporin A specifically inhibits function of the nuclear proteins involved in T cell activation. Science. 246:1617-1620.
4)Karttunen J and Shastri N (1991) Measurement of ligand-induced activation in single viable T cells using the lacZ reporter gene. Proc Natl Acad Sci USA.
88:3972.
5)Lenardo MJ and Baltimaore D (1989) NF-kB: a pleiotropic mediator of inducible and tissue specific gene control. Cell. 58: 227-229.
(上記文献はいずれも引用により本明細書に含まれる。)
マウス(NC/NgaTndCrlj、雄性)の塩化ピクリル(PiCl)誘発アトピー性皮膚炎モデルを用いて、皮膚炎症に対する効果および皮膚炎症を起こしている皮膚における毛の状態を評価した。
(1) 掻痒行動:2 分間の行動を観察し、誘発部位を掻く行動を観察
0:無症状: 誘発部位に対する掻痒行動が見られない状態
1:軽 度: 連続的な掻痒行動が 2 回以上で、累積で約1分を超えない行動
2:中等度: 累積で約1分を超え、約 1 分半を超えない行動
3:重 度: 累積で約1分半を超えるか、2 分間掻き続ける行動
(2) 発赤・出血:誘発部位の発赤および出血症状を観察
0:無症状: 誘発部位に発赤および出血症状が認められない状態
1:軽 度: 誘発部位に局所的に認められるか、連続的な擦傷に伴う出血が認められない状態
2:中等度: 誘発部位に散在的に認められるか、局所的に連続的な擦傷に伴う発赤および出血症状が認められる状態
3:重 度: 誘発部位に全体的に認められるか、連続的な擦傷が広範囲に広がり、発赤および出血症状が認められる状態
(3) 浮腫:誘発部位である耳介の浮腫を定性的に観察
0:無症状: 左右の耳介に厚みが認められない状態
1:軽 度: 左右のどちらか 1 方にわずかに厚みが認められる状態
2:中等度: いずれの耳介にも明らかな厚み、張りが認められる状態
3:重 度: いずれの耳介にも明らかな厚み、張りおよび反りが認められ、指で触れたときに硬さが感じられる状態
(4) 擦傷・組織欠損:誘発部位の擦傷および組織欠損症状を観察
0:無症状: 誘発部位に擦傷および組織欠損症状が認められない状態
1:軽 度: 誘発部位に局所的に認められ、連続的でない擦傷が認められ、組織欠損は認められない状態
2:中等度: 誘発部位に散在的に認められるか、小規模に連続的な擦傷が認められ、組織欠損は認められない状態
3:重 度: 誘発部位に全体的に認められるか、連続的な擦傷が広範囲に広がり、組織欠損が認められる状態
(5) 痂皮形成・乾燥:誘発部位の痂皮形成および乾燥症状を観察
0:無症状: 誘発部位の痂皮形成および乾燥症状なし
1:軽 度: 誘発部位に局所的に認められ、誘発部位の皮膚がわずかに白色化、角質の剥離がわずかに認められる状態
2:中等度: 誘発部位に散在的に認められるか、明らかに角質の剥離が認められる状態
3:重 度: 誘発部位に全体的に認められるか、明らかに角質の剥離が認められる状態
0:発毛、育毛が観察部位で観察できない
1:発毛、育毛が観察部位の 0<25%
2:発毛、育毛が観察部位の 25 ≦75%
3:発毛、育毛が観察部位の 75≦100%
Claims (17)
- 下記一般式(I)で表される脂肪酸誘導体を有効成分として含有する免疫抑制するための医薬組成物。
[式中、L、MおよびNは、水素、ヒドロキシ、ハロゲン、低級アルキル、ヒドロキシ(低級)アルキル、低級アルカノイルオキシまたはオキソ; ここで、LおよびMの少なくとも一方は水素以外の基であり、5員環は少なくとも1つの二重結合を有していてもよい;
Aは、-CH3、-CH2OH、-COCH2OH、-COOH またはそれらの官能性誘導体;
Bは、単結合、-CH2-CH2-、-CH=CH-、-C≡C-、-CH2-CH2-CH2-、-CH=CH-CH2-、-CH2-CH=CH-、-C≡C-CH2-または-CH2-C≡C-;
Z1およびZ2は、酸素、窒素または硫黄;
R2およびR3は低級アルキルであり、一緒につながって低級アルキレンを形成してもよい;
R1は、非置換またはハロゲン、アルキル、ヒドロキシ、オキソ、アリールまたは複素環基で置換された、飽和または不飽和の二価の低~中級脂肪族炭化水素であり、脂肪族炭化水素における少なくとも1つの炭素原子は酸素、窒素または硫黄で置換されていてもよい;および、
Raは、非置換またはハロゲン、オキソ、ヒドロキシ、低級アルキル、低級アルコキシ、低級アルカノイルオキシ、シクロ(低級)アルキル、シクロ(低級)アルキルオキシ、アリール、アリールオキシ、複素環基または複素環オキシ基で置換された飽和または不飽和の低~中級脂肪族炭化水素残基; 低級アルコキシ; 低級アルカノイルオキシ; シクロ(低級)アルキル; シクロ(低級)アルキルオキシ; アリール; アリールオキシ; 複素環基; 複素環オキシ基]。 - LおよびMがヒドロキシである、請求項1記載の医薬組成物。
- Aが-COOH またはその官能性誘導体である、請求項1または2記載の医薬組成物。
- Bが-CH2-CH2-、-CH=CH-または-C≡C-である、請求項1~3のいずれかに記載の医薬組成物。
- Z1およびZ2が酸素である、請求項1~4のいずれかに記載の医薬組成物。
- R2およびR3が一緒につながって低級アルキレンを形成する、請求項1~5のいずれかに記載の医薬組成物。
- 低級アルキレンが炭素数3のアルキレンである、請求項6記載の医薬組成物。
- 脂肪酸誘導体がイソプロピル (Z)-7-[(1R,2R,3R,5S)-2-(3,3-エチレンジオキシデシル)-3,5-ジヒドロキシシクロペンチル]ヘプト-5-エノエートである、請求項1~7のいずれかに記載の医薬組成物。
- 炎症性疾患を処置するためのものである、請求項1~8のいずれかに記載の医薬組成物。
- 皮膚の炎症またはそれに伴う脱毛症を処置するためのものである、請求項9記載の医薬組成物。
- 皮膚の炎症に伴う脱毛症を処置するためのものである、請求項10記載の医薬組成物。
- アレルギー性疾患を処置するためのものである、請求項1~8のいずれかに記載の医薬組成物。
- アトピー性皮膚炎またはそれに伴う脱毛症を処置するためのものである、請求項12記載の医薬組成物。
- アトピー性皮膚炎に伴う脱毛症を処置するためのものである、請求項13記載の医薬組成物。
- 自己免疫疾患を処置するためのものである、請求項1~8のいずれかに記載の医薬組成物。
- 有効量の請求項1記載の一般式(I)で表される脂肪酸誘導体を必要とする対象に投与することを含む、哺乳類対象において免疫抑制する方法。
- 哺乳類対象において免疫抑制するための、請求項1記載の一般式(I)で表される脂肪酸誘導体の使用。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/128,257 US20140212441A1 (en) | 2011-06-21 | 2012-06-20 | Pharmaceutical composition for inflammatory diseases, allergic diseases and autoimmune diseases |
EP12802941.0A EP2730283A4 (en) | 2011-06-21 | 2012-06-20 | PHARMACEUTICAL COMPOSITION FOR INFLAMMATORY DISEASES, ALLERGIC DISEASES AND AUTOIMMUNE DISEASES |
KR1020147000312A KR20140048196A (ko) | 2011-06-21 | 2012-06-20 | 염증성 질환, 알레르기성 질환 및 자가면역 질환을 위한 약학적 조성물 |
CN201280040800.5A CN103974705A (zh) | 2011-06-21 | 2012-06-20 | 用于炎症性疾病、过敏性疾病和自身免疫性疾病的药物组合物 |
CA2840875A CA2840875A1 (en) | 2011-06-21 | 2012-06-20 | Pharmaceutical composition for inflammatory diseases, allergic diseases and autoimmune diseases |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011137213 | 2011-06-21 | ||
JP2011-137213 | 2011-06-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012176792A1 true WO2012176792A1 (ja) | 2012-12-27 |
Family
ID=47422624
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2012/065706 WO2012176792A1 (ja) | 2011-06-21 | 2012-06-20 | 炎症性疾患、アレルギー性疾患および自己免疫疾患用途のための医薬組成物 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20140212441A1 (ja) |
EP (1) | EP2730283A4 (ja) |
JP (1) | JPWO2012176792A1 (ja) |
KR (1) | KR20140048196A (ja) |
CN (1) | CN103974705A (ja) |
CA (1) | CA2840875A1 (ja) |
TW (1) | TW201309301A (ja) |
WO (1) | WO2012176792A1 (ja) |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4088775A (en) | 1974-07-12 | 1978-05-09 | Schering Aktiengesellschaft | 15-Ethylenedioxy-prostanoic acid derivatives and esters thereof and intermediates thereof |
US4870104A (en) | 1983-07-08 | 1989-09-26 | Schering Aktiengesellschaft | 11-haloprostane derivatives, processes for their preparation and their use as medicinal agents |
EP0454429A2 (en) * | 1990-04-27 | 1991-10-30 | Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo | Use of 15-dehydroxy-16-oxoprostaglandin derivatives in the treatment of allergic diseases |
EP0467564A2 (en) * | 1990-07-10 | 1992-01-22 | R-Tech Ueno Ltd. | Treatment of inflammatory diseases with 15-keto-prostaglandin compounds |
JPH0770054A (ja) * | 1993-08-30 | 1995-03-14 | R Tec Ueno:Kk | 生化学的拮抗および疾患処置剤 |
US6353014B1 (en) | 1996-11-12 | 2002-03-05 | Alcon Laboratories, Inc. | 15-ketal postaglandins for the treatment of glaucoma or ocular hypertension |
WO2005013928A1 (en) | 2003-08-12 | 2005-02-17 | Sucampo Ag | Composition and method for promoting hair growth |
WO2006070942A1 (en) | 2004-12-29 | 2006-07-06 | R-Tech Ueno, Ltd | Composition and method for scalp and hair treatment |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2328132A1 (de) * | 1973-05-30 | 1975-01-02 | Schering Ag | Neue prostansaeurederivate und verfahren zu ihrer herstellung |
LU87090A1 (fr) * | 1987-12-22 | 1989-07-07 | Oreal | Association de derives de pyrimidine et d'agents anti-inflammatoires non steroidiens pour induire et stimuler la croissance des cheveux et diminuer leur chute |
WO2000030636A1 (en) * | 1998-11-20 | 2000-06-02 | The General Hospital Corporation | Use of pyrethroid compounds to promote hair growth |
JP2003500432A (ja) * | 1999-06-01 | 2003-01-07 | ザ・ユニバーシティ・オブ・テキサス・サウスウエスタン・メディカル・センター | ジフェニルエーテル誘導体を用いて脱毛症を処置する方法 |
CN101160114B (zh) * | 2004-12-29 | 2013-02-06 | 株式会社·R-技术上野 | 头皮和毛发处理组合物及方法 |
JP2009084298A (ja) * | 2009-01-28 | 2009-04-23 | Tsujido Kagaku Kk | 養毛・育毛剤 |
-
2012
- 2012-06-20 CA CA2840875A patent/CA2840875A1/en not_active Abandoned
- 2012-06-20 US US14/128,257 patent/US20140212441A1/en not_active Abandoned
- 2012-06-20 EP EP12802941.0A patent/EP2730283A4/en not_active Withdrawn
- 2012-06-20 KR KR1020147000312A patent/KR20140048196A/ko not_active Application Discontinuation
- 2012-06-20 WO PCT/JP2012/065706 patent/WO2012176792A1/ja active Application Filing
- 2012-06-20 CN CN201280040800.5A patent/CN103974705A/zh active Pending
- 2012-06-20 TW TW101122004A patent/TW201309301A/zh unknown
- 2012-06-20 JP JP2013521593A patent/JPWO2012176792A1/ja active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4088775A (en) | 1974-07-12 | 1978-05-09 | Schering Aktiengesellschaft | 15-Ethylenedioxy-prostanoic acid derivatives and esters thereof and intermediates thereof |
US4870104A (en) | 1983-07-08 | 1989-09-26 | Schering Aktiengesellschaft | 11-haloprostane derivatives, processes for their preparation and their use as medicinal agents |
EP0454429A2 (en) * | 1990-04-27 | 1991-10-30 | Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo | Use of 15-dehydroxy-16-oxoprostaglandin derivatives in the treatment of allergic diseases |
EP0467564A2 (en) * | 1990-07-10 | 1992-01-22 | R-Tech Ueno Ltd. | Treatment of inflammatory diseases with 15-keto-prostaglandin compounds |
JPH0770054A (ja) * | 1993-08-30 | 1995-03-14 | R Tec Ueno:Kk | 生化学的拮抗および疾患処置剤 |
US6353014B1 (en) | 1996-11-12 | 2002-03-05 | Alcon Laboratories, Inc. | 15-ketal postaglandins for the treatment of glaucoma or ocular hypertension |
WO2005013928A1 (en) | 2003-08-12 | 2005-02-17 | Sucampo Ag | Composition and method for promoting hair growth |
WO2006070942A1 (en) | 2004-12-29 | 2006-07-06 | R-Tech Ueno, Ltd | Composition and method for scalp and hair treatment |
Non-Patent Citations (6)
Title |
---|
"Cell Proliferation in Selected Methods in Cellular Immunology", vol. XXIX, 1980, W.H. FREEMAN CO., pages: 153 - 160 |
DAYTON JS; TURKA LA; THOMPSON CB; MITCHELL BS: "Comparison of the effects of myoribine with those of zothiaprine, 6 mercaptopurine and mycophenolic acid on T-lymphocyte proliferation and purine ribonucleotide metabolism", MOL PHARMACOL., vol. 41, 1992, pages 671 - 676 |
EMMEL EA; VERWEIJ CL; DURAND DB; HIGGINS KM; LACY E; CRABTREE GR: "Cyclosporin A specifically inhibits function of the nuclear proteins involved in T cell activation", SCIENCE, vol. 246, 1989, pages 1617 - 1620 |
KARTTUNEN J; SHASTRI N: "Measurement of ligand- induced activation in single viable T cells using the lacZ reporter gene", PROC NATL ACAD SCI USA., vol. 88, 1991, pages 3972 |
LENARDO MJ; BALTIMAORE D: "NF-kB: a pleiotropic mediator of inducible and tissue specific gene control", CELL, vol. 58, 1989, pages 227 - 229 |
See also references of EP2730283A4 |
Also Published As
Publication number | Publication date |
---|---|
EP2730283A4 (en) | 2015-06-03 |
CN103974705A (zh) | 2014-08-06 |
US20140212441A1 (en) | 2014-07-31 |
JPWO2012176792A1 (ja) | 2015-02-23 |
CA2840875A1 (en) | 2012-12-27 |
TW201309301A (zh) | 2013-03-01 |
EP2730283A1 (en) | 2014-05-14 |
KR20140048196A (ko) | 2014-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5318837B2 (ja) | 育毛を促進する組成物および方法 | |
KR101354771B1 (ko) | 중추 신경계 질환 치료를 위한 방법 및 조성물 | |
KR100195430B1 (ko) | 15-케토-프로스타글란딘 화합물에 의한 염증성 질환 치료 | |
US6956056B2 (en) | Method for providing a cathartic effect | |
AU2017203092B2 (en) | Method for treating schizophrenia | |
WO2012176792A1 (ja) | 炎症性疾患、アレルギー性疾患および自己免疫疾患用途のための医薬組成物 | |
WO2015050277A1 (en) | Selective tumor treatment | |
EP0454429A2 (en) | Use of 15-dehydroxy-16-oxoprostaglandin derivatives in the treatment of allergic diseases | |
WO2016067620A1 (en) | Method and composition for treating nonerosive reflux disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12802941 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2013521593 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2840875 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 20147000312 Country of ref document: KR Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2012802941 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012802941 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14128257 Country of ref document: US |